Pharmaceuticals, Biotechnology and Life Sciences
Lysogene posted net loss, for the first half of 2019 which amounted to €1.9 million compared to €7.2 million in the first half of 2018, with €6.8 million revenues in the first half 2019.
Transgene posted promising result at ESMO, of TG4001 plus Bavencio (avelumab) in HPV-16 positive cancers, from a clinical trial conducted…
AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair…
Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.
Novartis will present results from its trial designated Mnaleesa-3, which showed that ribociclib branded as Kisqali has achieved statistically significant improvement in overall survival (OS), which is – according to Novartis – the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials — consistently demonstrating approximately 30% reduction in the risk of death.
Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer
Noxxon will present latest Clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress on Monday at 09.00 A.M., which shows that the combination of NOX-A12 and pembrolizumab induced an immune response, stable disease in 25% of patients and prolonged time on treatment vs. prior therapy for 35% of patients.
The updated data from Clovis’s TRITON2 trial confirm the potential role of rucaparib in treating metastatic castration-resistant prostate cancer
– Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models – Early analysis of…
Zymerowks’ data for HER2-targeted biospecific antibody ZW25, which will be presented at ESMO, support the Initiation of a Registration-Enabling Phase 2 Trial of the ZW25 in second-line HER2-expressing biliary tract cancers.